Li Kang Biomedical Co Ltd (6242) - Net Assets
Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has net assets worth NT$843.61 Million TWD (≈ $26.58 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.16 Billion ≈ $36.45 Million USD) and total liabilities (NT$313.41 Million ≈ $9.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Li Kang Biomedical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$843.61 Million |
| % of Total Assets | 72.91% |
| Annual Growth Rate | 4.18% |
| 5-Year Change | 68.34% |
| 10-Year Change | 205.28% |
| Growth Volatility | 177.19 |
Li Kang Biomedical Co Ltd - Net Assets Trend (2002–2024)
This chart illustrates how Li Kang Biomedical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Li Kang Biomedical Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Li Kang Biomedical Co Ltd (2002–2024)
The table below shows the annual net assets of Li Kang Biomedical Co Ltd from 2002 to 2024. For live valuation and market cap data, see Li Kang Biomedical Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$855.68 Million ≈ $26.96 Million |
+35.82% |
| 2023-12-31 | NT$630.03 Million ≈ $19.85 Million |
+10.51% |
| 2022-12-31 | NT$570.14 Million ≈ $17.96 Million |
+15.88% |
| 2021-12-31 | NT$492.00 Million ≈ $15.50 Million |
-3.21% |
| 2020-12-31 | NT$508.30 Million ≈ $16.01 Million |
+5.14% |
| 2019-12-31 | NT$483.44 Million ≈ $15.23 Million |
+3.54% |
| 2018-12-31 | NT$466.92 Million ≈ $14.71 Million |
+4.77% |
| 2017-12-31 | NT$445.68 Million ≈ $14.04 Million |
+30.77% |
| 2016-12-31 | NT$340.80 Million ≈ $10.74 Million |
+21.59% |
| 2015-12-31 | NT$280.29 Million ≈ $8.83 Million |
+23.24% |
| 2014-12-31 | NT$227.44 Million ≈ $7.17 Million |
+836.40% |
| 2013-12-31 | NT$24.29 Million ≈ $765.24K |
-71.46% |
| 2012-12-31 | NT$85.12 Million ≈ $2.68 Million |
-31.04% |
| 2011-12-31 | NT$123.43 Million ≈ $3.89 Million |
+18.33% |
| 2010-12-31 | NT$104.31 Million ≈ $3.29 Million |
-18.81% |
| 2009-12-31 | NT$128.49 Million ≈ $4.05 Million |
-32.84% |
| 2008-12-31 | NT$191.32 Million ≈ $6.03 Million |
-53.51% |
| 2007-12-31 | NT$411.54 Million ≈ $12.97 Million |
+90.57% |
| 2006-12-31 | NT$215.94 Million ≈ $6.80 Million |
-3.36% |
| 2005-12-31 | NT$223.45 Million ≈ $7.04 Million |
-30.91% |
| 2004-12-31 | NT$323.44 Million ≈ $10.19 Million |
-4.33% |
| 2003-12-31 | NT$338.06 Million ≈ $10.65 Million |
-2.76% |
| 2002-12-31 | NT$347.64 Million ≈ $10.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Li Kang Biomedical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 436.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$254.28 Million | 29.72% |
| Other Components | NT$601.40 Million | 70.28% |
| Total Equity | NT$855.68 Million | 100.00% |
Li Kang Biomedical Co Ltd Competitors by Market Cap
The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LAVA THERAP. B.V. EO-12
F:4PKB
|
$38.54 Million |
|
Watos Corea Co. Ltd
KQ:079000
|
$38.55 Million |
|
Uniti SA
PA:ALUNT
|
$38.55 Million |
|
enX Group Ltd
JSE:ENX
|
$38.55 Million |
|
Kafein Yazilim
IS:KFEIN
|
$38.53 Million |
|
Ascent Solar Technologies, Inc. Common Stock
NASDAQ:ASTI
|
$38.51 Million |
|
Jinli Group Holdings Ltd
TW:8429
|
$38.51 Million |
|
Covalon Technologies Ltd.
V:COV
|
$38.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Li Kang Biomedical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 630,032,000 to 855,683,000, a change of 225,651,000 (35.8%).
- Net income of 77,024,000 contributed positively to equity growth.
- Dividend payments of 79,517,000 reduced retained earnings.
- New share issuances of 225,000,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$77.02 Million | +9.0% |
| Dividends Paid | NT$79.52 Million | -9.29% |
| Share Issuances | NT$225.00 Million | +26.29% |
| Other Changes | NT$3.14 Million | +0.37% |
| Total Change | NT$- | 35.82% |
Book Value vs Market Value Analysis
This analysis compares Li Kang Biomedical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.92x to 1.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$20.08 | NT$38.45 | x |
| 2018-12-31 | NT$21.03 | NT$38.45 | x |
| 2019-12-31 | NT$17.32 | NT$38.45 | x |
| 2020-12-31 | NT$18.21 | NT$38.45 | x |
| 2021-12-31 | NT$17.67 | NT$38.45 | x |
| 2022-12-31 | NT$20.45 | NT$38.45 | x |
| 2023-12-31 | NT$22.60 | NT$38.45 | x |
| 2024-12-31 | NT$26.90 | NT$38.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Li Kang Biomedical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.00%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.62%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.21x
- Recent ROE (9.00%) is below the historical average (15.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 5.60% | 2.07% | 1.23x | 2.20x | NT$-15.31 Million |
| 2015 | 18.86% | 11.60% | 0.87x | 1.88x | NT$24.82 Million |
| 2016 | 18.05% | 13.65% | 0.81x | 1.63x | NT$27.43 Million |
| 2017 | 30.01% | 26.97% | 0.83x | 1.34x | NT$89.17 Million |
| 2018 | 16.43% | 15.48% | 0.81x | 1.31x | NT$30.05 Million |
| 2019 | 14.90% | 14.90% | 0.77x | 1.30x | NT$23.67 Million |
| 2020 | 13.63% | 15.17% | 0.71x | 1.27x | NT$18.44 Million |
| 2021 | 10.45% | 13.29% | 0.63x | 1.25x | NT$2.24 Million |
| 2022 | 19.66% | 16.38% | 0.99x | 1.21x | NT$55.08 Million |
| 2023 | 17.62% | 17.64% | 0.76x | 1.31x | NT$47.99 Million |
| 2024 | 9.00% | 13.62% | 0.55x | 1.21x | NT$-8.54 Million |
Industry Comparison
This section compares Li Kang Biomedical Co Ltd's net assets metrics with peer companies in the Travel Services industry.
Industry Context
- Industry: Travel Services
- Average net assets among peers: $1,288,898,000
- Average return on equity (ROE) among peers: 13.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Li Kang Biomedical Co Ltd (6242) | NT$843.61 Million | 5.60% | 0.37x | $38.53 Million |
| Lion Travel Service Co Ltd (2731) | $2.26 Billion | 9.69% | 2.88x | $467.26 Million |
| Richmond International Travel & Tours Co Ltd (2743) | $533.28 Million | 10.78% | 1.83x | $105.02 Million |
| Phoenix Tours International Inc (5706) | $1.07 Billion | 20.03% | 0.53x | $136.17 Million |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded i… Read more